Simon Bowler
A5033155832- Asthma and respiratory diseases
- Cystic Fibrosis Research Advances
- Respiratory and Cough-Related Research
- Respiratory viral infections research
- Influenza Virus Research Studies
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Pneumonia and Respiratory Infections
- Inhalation and Respiratory Drug Delivery
- Neonatal Respiratory Health Research
- IL-33, ST2, and ILC Pathways
- Allergic Rhinitis and Sensitization
- Smoking Behavior and Cessation
- Tracheal and airway disorders
- Emergency and Acute Care Studies
- Pediatric health and respiratory diseases
- Data-Driven Disease Surveillance
- COVID-19 epidemiological studies
- Frailty in Older Adults
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Congenital Diaphragmatic Hernia Studies
- Nosocomial Infections in ICU
- Tuberous Sclerosis Complex Research
- Vaccine Coverage and Hesitancy
- Obstructive Sleep Apnea Research
- Cytomegalovirus and herpesvirus research
Mater Adult Hospital
2011-2023
Mater Hospital
2013-2022
Monash Alfred Psychiatry Research centre
2022
The Alfred Hospital
2022
Monash University
2019-2022
The University of Queensland
1998-2021
Mater Research
2012-2021
Translational Research Institute
2021
Mater Private Hospital
2021
The University of Western Australia
2018-2019
Macrolide antibiotics such as erythromycin may improve clinical outcomes in non-cystic fibrosis (CF) bronchiectasis, although associated risks of macrolide resistance are poorly defined.To evaluate the efficacy and antimicrobial cost low-dose given for 12 months to patients with non-CF bronchiectasis a history frequent pulmonary exacerbations.Twelve-month, randomized (1:1), double-blind, placebo-controlled trial currently nonsmoking, adult 2 or more infective exacerbations preceding year....
Severe asthma is a high-burden disease. Real-world data on mepolizumab in patients with severe eosinophilic needed to assess whether the from randomised controlled trials are applicable broader population. The Australian Mepolizumab Registry (AMR) was established an aim use, effectiveness and safety of for Australia. Patients (n=309) (median age 60 years, 58% female) commenced mepolizumab. They had poor symptom control Asthma Control Questionnaire (ACQ)-5 score 3.4), frequent exacerbations...
Current treatments for idiopathic pulmonary fibrosis slow the rate of lung function decline, but may be associated with adverse events that affect medication adherence. In phase 2 trials, pamrevlumab (a fully human monoclonal antibody binds to and inhibits connective tissue growth factor activity) attenuated progression without substantial events.
Rationale: Non-cystic fibrosis bronchiectasis is characterized by airway mucus accumulation and sputum production, but the role of concentration in pathogenesis these abnormalities has not been characterized.Objectives: This study was designed to: 1) measure biophysical properties mucus; 2) identify secreted mucins contained 3) relate to epithelial mucin RNA/protein expression; 4) explore relationships between hyperconcentration disease severity.Methods: Sputum samples were collected from...
Abstract Background Asthma remission has emerged as a potential treatment goal. This study evaluated the effectiveness of two biologics (mepolizumab/omalizumab) in achieving asthma remission. Methods observational included 453 severe patients (41% male; mean age ± SD 55.7 14.7 years) from real‐world drug registries: Australian Mepolizumab Registry and Xolair Registry. The composite outcome clinical was defined zero exacerbations oral corticosteroids during previous 6 months assessed at 12...
SARS-CoV-2 variants evade immunity despite vaccination with prototype COVID-19 vaccines or previous infection. The 2019nCoV-311 (part 2) study is evaluating immune responses after two booster doses of a vaccine containing the omicron BA.5 subvariant spike protein in adults previously vaccinated mRNA vaccine. This interim analysis reports on day 28 immunogenicity and safety outcomes one dose.
Objective To evaluate the effect of Buteyko breathing techniques (BBT) in management asthma. Design Prospective, blinded, randomised study comparing BBT with control classes 39 subjects The was conducted from January 1995 to April 1995. Participants and setting Subjects recruited community, aged 12 70 years, asthma substantial medication use. Main outcome measures Medication use; morning peak expiratory flow (PEF); forced volume one second (FEV1); end-tidal (ET) CO2; resting minute (MV);...
Although heparin is used as an anticoagulant, its biologic function remains unclear. Substantial evidence exists that suggests it may modulate many aspects of immune and inflammation. We demonstrated, in a double-blind, placebo-controlled, crossover study involving 10 allergic subjects, small dose (25 U/kg) administered intravenously min before challenge reduced the acute cutaneous reaction to allergens histamine from group-average sum mean (± SD) wheal diameters at baseline 29.9 ± mm after...
Severe asthma is a high impact disease. Omalizumab targets the allergic inflammatory pathway; however, effectiveness data in population with significant comorbidities are limited.To describe severe asthma, omalizumab treatment outcomes and predictors of response among Australian Xolair Registry participants.A web-based post-marketing surveillance registry was established to characterise use, adverse effects (Xolair) for asthma.Participants (n = 192) (mean age 51 years, 118 female) from 21...
Rationale: The alarmins IL-33 and HMGB1 (high mobility group box 1) contribute to type 2 inflammation asthma pathogenesis. Objectives: To determine whether P2Y13-R (P2Y13 receptor), a purinergic GPCR (G protein–coupled receptor) risk allele for asthma, regulates the release of HMGB1. Methods: Bronchial biopsy specimens were obtained from healthy subjects with asthma. Primary human airway epithelial cells (AECs), primary mouse AECs, or C57Bl/6 mice inoculated various aeroallergens respiratory...
IntroductionPersistent cough with sputum production is an important clinical trait in chronic obstructive pulmonary disease (COPD). We defined “frequent productive cough” based on 2 questions from the St George's Respiratory Questionnaire (SGRQ) and sought to determine its occurrence associated outcomes patients physician-assigned asthma and/or COPD NOVELTY study.MethodsFrequent was as most or several days/week for past 3 months (scoring ≥3 both SGRQ questions). Relationships baseline...
In 2017, Australia experienced record influenza notifications. Two surveillance programs combined to summarize the epidemiology of hospitalized in children and report on vaccine effectiveness (VE) context a limited nationally funded vaccination program.Subjects were prospectively recruited (April-October 2017). Case patients aged ≤16 years admitted 11 hospitals with an acute respiratory illness laboratory-confirmed influenza. Controls tested negative for VE estimates calculated using...
Autosomal dominant hereditary sensory neuropathy (HSN I) is a clinically and genetically heterogeneous group of disorders, in some families it due to mutations the serine palmitoyltransferase (SPTLC1) gene. We have characterized two with HSN I associated cough gastro-oesophageal reflux (GOR). From large Australian family, 27 individuals from smaller 11 provided clinical information blood for genetic analysis. Affected had an adult onset paroxysmal cough, GOR distal loss. Cough could be...
Annual influenza vaccine is recommended for those at greatest risk of severe infection. Recent reports a negative impact serial vaccination on effectiveness (VE) raises concerns about the recommendation annual vaccines, particularly in persons risk. The Influenza Complications Alert Network (FluCAN) an Australian hospital-based sentinel surveillance program. In this observational study, cases were defined as subjects aged >9 years admitted with confirmed by polymerase chain reaction....
The Influenza Complications Alert Network (FluCAN) is a sentinel-hospital-based surveillance program that operates at sites in all jurisdictions Australia. This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during 2017 season. In this observational system, cases were defined as patients admitted to any 17 sentinel hospitals confirmed by nucleic acid detection. Data are also collected on frequency-matched control group influenza-negative acute...
Abstract Background No short patient-reported outcome (PRO) instruments assess overall health status across different obstructive lung diseases. Thus, the wording of introduction to Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) was modified permit use in asthma and/or COPD. This tool is called Airways (CAAT). Methods The psychometric properties CAAT were evaluated using baseline data from NOVELTY study (NCT02760329) patients with physician-assigned asthma, + COPD or...
The respiratory abilities of a group 19 speech-disordered subjects with idiopathic Parkinson's disease were assessed using both spirometric and kinematic techniques compared to those nonneurologically impaired controls matched for age sex. Results the assessment showed that only minority had lung volumes capacities outside normal limits. Consequently in majority eases, speech disorder could not be related any abnormality function determined spirometrically. Chest wall dynamics during...
Four randomised, placebo-controlled trials have previously documented the clinical benefits of azithromycin (AZM) in cystic fibrosis (CF) patients. The present study examined whether beneficial effect AZM is equivalent when administered daily or weekly. A double-blind, randomised was carried out 208 CF patients aged 6-58 yrs who were assigned to either 250 mg (n = 103) 1,200 weekly 105) for 6 months, with assessments at baseline and 1, 3, 7 months. Patients taken from five adult children...
Section:ChooseTop of pageAbstract <<PAST PANDEMIC INFLUENZA A...BROAD CLINICAL SPECTRUM O...SPECIFIC H1N1_09 MANAGEME...PANDEMIC INFLUENZA, HEALT...ROLE OF RESPIRATORY COMMU...CONCLUSIONSReferencesCITING ARTICLES
Summary Background Omalizumab (Xolair) dosing in severe allergic asthma is based on serum IgE and bodyweight. In Australia, patients eligible for omalizumab but exceeding recommended ranges (30–1500 IU/mL) bodyweight (30–150 kg) may still receive a ceiling dose of 750 mg/4 weeks. About 62% receiving government‐subsidized are enrolled the Australian Xolair Registry ( AXR ). Objectives To determine whether participants above benefit from to compare their response within‐range participants....
The Influenza Complications Alert Network (FluCAN) is a sentinel hospital-based surveillance program that operates at sites in all jurisdictions Australia. This report summarises the epidemiology of hospitalisations with laboratory-confirmed influenza during 2018 season. In this observational system, cases were defined as patients admitted to any 17 hospitals confirmed by nucleic acid detection. Data also collected on frequency-matched control group influenza-negative acute respiratory...
Rationale: The mechanism by which low-dose macrolide therapy reduces exacerbations in non–cystic fibrosis bronchiectasis is not known. Pseudomonas aeruginosa quorum sensing controls the expression of a range pathogenicity traits and inhibited vitro. Quorum inhibition renders P. less pathogenic, potentially reducing its contribution to airway damage.Objectives: aim this study was determine whether long-term erythromycin inhibits within airways patients with bronchiectasis.Methods: Analysis...
This trial compared the cost of an integrated home-based care model with traditional inpatient for acute chronic obstructive pulmonary disease (COPD). 25 patients COPD were randomised to either home or hospital management following request admission. The at group costs per separation ($745, CI95% $595-$895, n = 13) significantly lower (p < 0.01) than ($2543, $1766-$3321, 12). There was improvement in lung function hospital-managed Outpatient Department review, decreased anxiety Emergency...
Although the need for corticosteroids in acute severe asthma is well established appropriate dose not known.The response to intravenous hydrocortisone 50 mg (low dose), 100 (medium and 500 (high administered every six hours 48 followed by oral prednisone, was compared patients with a double blind randomised study. After initial emergency treatment bronchodilators subjects received theophylline or aminophylline nebulised salbutamol four hourly. Patients were given low, medium, high doses of...